Izonsteride

CAS No. 176975-26-1

Izonsteride( —— )

Catalog No. M34293 CAS No. 176975-26-1

Izonsteride (LY320236) is a selective and potent 5alpha reductase inhibitor with dual action on the type I and type II isoforms of the enzyme.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 243 Get Quote
5MG 380 Get Quote
10MG 570 Get Quote
25MG 882 Get Quote
50MG 1178 Get Quote
100MG 1575 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Izonsteride
  • Note
    Research use only, not for human use.
  • Brief Description
    Izonsteride (LY320236) is a selective and potent 5alpha reductase inhibitor with dual action on the type I and type II isoforms of the enzyme.
  • Description
    Izonsteride (LY320236) is a selective and potent 5alpha reductase inhibitor with dual action on the type I and type II isoforms of the enzyme.Izonsteride is used in the treatment of oncology and genitourinary disorders, and may be used in the study of prostate cancer.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Endocrinology/Hormones
  • Target
    Reductase
  • Recptor
    Reductase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    176975-26-1
  • Formula Weight
    422.61
  • Molecular Formula
    C24H26N2OS2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C[C@@]12C=3C(=CC(SC4=NC=5C(S4)=CC=CC5CC)=CC3)CC[C@]1(N(C)C(=O)CC2)[H]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Difubenzuron

    Diflubenzuron is a benzoyl-urea insecticide, found to be a potent inhibitor of melanosome synthesis in mouse melanoma cells.

  • BYAKANGELICIN(b)

    BYAKANGELICINa main furanocoumarin constituent isolated and characterized as an aldose reductase inhibitorand is effective for the treatment of sugar cataracts and diabetic neuropathy and hence might be useful as a lead compound for the development of new type drugs for clinical use.

  • Ponalrestat

    ponalrestat, an aldose reductase inhibitor, activates lipoprotein lipase (LPL) activity in the adipose tissue and alleviates the cachectic symptoms induced by B16 melanoma in mice